HOYA
SURGICAL OPTICS

Vivinex™ MODEL **XC1** | MODEL **XY1**

Vivinex™ iSert®

VIVINEX™ OFFERS CLARITY OF VISION

- **Glistening-free hydrophobic** acrylic IOL material[1,2]
- **Proprietary aspheric optic design** for improved image quality[3]
- **Active oxygen processing treatment**, a **smooth surface** and **square optic edge** to reduce PCO[2,4,5,6,7,8,9,10]
- **Vivinex™ iSert®** provides **outstanding delivery consistency**

HOYA SURGICAL OPTICS

Vivinex™ MODEL **XC1** | MODEL **XY1**





Vivinex™ iSert®



Vivinex™ iSert®

Model name	XC1 | XY1			
Optic design	Aspheric design with square, thin and textured optic edge			
Optic & haptic materials	Hydrophobic acrylic Vivinex™ with UV-filter (Model XC1), with UV- and blue light filter (Model XY1)			
Haptic design	Textured-rough haptic surface			
Diameter (optic/OAL)	6.00 mm / 13.00 mm			
Power	+6.00 to +30.00 D (in 0.50 D increments)			
Nominal A-constant*	118.9			
Optimized constants**	Haigis	a_0 = -0.8028	a_1 = 0.2133	a_2 = 0.2245
	Hoffer Q	pACD = 5.697		
	Holladay 1	sf = 1.934		
	SRK/T	A = 119.198		
Injector	**Vivinex™ iSert®** preloaded			
Front injector tip outer diameter	1.70 mm			
Recommended incision size	2.20 mm			

1 Tandogan, T. et al. (2021): In-vitro glistening formation in six different foldable hydrophobic intraocular lenses. In BMC Ophthalmol 21, 126
2 HOYA data on file. DoF-CTM-21-002, HOYA Medical Singapore Pte. Ltd, 2021
3 Pérez-Merino, P.; Marcos, S. (2018): Effect of intraocular lens decentration on image quality tested in a custom model eye. In: Journal of cataract and refractive surgery 44 (7), p. 889–896.
4 Leydolt, C. et al. (2020): Posterior capsule opacification with two hydrophobic acrylic intraocular lenses: 3-year results of a randomized trial. In: American journal of ophthalmology 217 (9), p. 224-231.
5 Nanavaty, M. et al. (2019): Edge profile of commercially available square-edged intraocular lenses: Part 2. In: Journal of cataract and refractive surgery 45 (6), p. 847–853.
6 Giacinto, C. et al. (2019): Surface properties of commercially available hydrophobic acrylic intraocular lenses: Comparative study. In: Journal of cataract and refractive surgery 45 (9), p. 1330–1334.
7 Werner, L. et al. (2019): Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commercially available IOLs. In: Journal of cataract and refractive surgery 45 (10), p. 1490–1497.
8 Matsushima, H. et al. (2006): Active oxygen processing for acrylic intraocular lenses to prevent posterior capsule opacification. In: Journal of cataract and refractive surgery 32 (6), p. 1035–1040.
9 Farukhi, A. et al. (2015): Evaluation of uveal and capsule biocompatibility of a single-piece hydrophobic acrylic intraocular lens with ultraviolet-ozone treatment on the posterior surface. In: Journal of cataract and refractive surgery 41 (5), p. 1081–1087.
10 Eldred, J. et al. (2019): An In Vitro Human Lens Capsular Bag Model Adopting a Graded Culture Regime to Assess Putative Impact of IOLs on PCO Formation. In: Investigative ophthalmology & visual science 60 (1), p. 113–122.

* The A-constant is presented as a starting point for the lens power calculation. When calculating the exact lens power, it is recommended that calculations be performed individually, based on the equipment used and operating surgeon's own experience.

** These optimized constants for the calculation of intraocular lens power published by IOLCon on their website: https://iolcon.org are calculated from 1,475 clinical results for Vivinex™ model XY1/XC1 as of September 24, 2021. These constants are based on actual surgical data and are provided by IOLCon as a starting point for individual constant optimizations. The information available on the website is based on data originating from other users and not by HOYA Surgical Optics ("HSO"). HSO therefore does not warrant the correctness, completeness and currentness of the contents on the said website.

Information contained is intended for health care professionals. For a full list of indications and contra indications please refer to the Instructions For Use. Some of the products and/or specific features as well as the procedures featured in this document may not be approved in your country and thus may not be available there. Design and specifications are subject to change without prior notice as a result of ongoing technical development. Please contact our regional representative regarding individual availability in your country. HOYA, Vivinex and iSert are trademarks of the HOYA Corporation or its affiliates.

HOYA Medical Singapore Pte. Ltd | 455A Jalan Ahmad Ibrahim | Singapore 639939

EC REP HOYA Surgical Optics GmbH | De-Saint-Exupéry-Straße 10 | 60549 Frankfurt am Main | Germany
Hotline DE: Tel. +49 (0)800 664 2 664 | Fax +49 (0)800 774 2 774

hoyasurgicaloptics.com

CE 0123

2021-09-27_HSOE_XC1_XY1_DS_EN